Fibrosis is a final common pathway in many forms of organ failure and a major cause of morbidity and mortality worldwide. Classically, fibrosis is characterized by aberrant fibroblast activation and inadequate tissue repair.
While advances have been made in the understanding of molecular mechanisms driving tissue injury and fibrosis, there remains a need to: 1) identify targets/pathways that are relevant to human disease and can be leveraged to promote repair and regeneration; and 2) develop translational strategies to facilitate clinical development of novel therapies.
• Share recent advances in the understanding of cellular and molecular mechanisms driving tissue injury and fibrosis and their potential to be leveraged to promote tissue repair and regeneration.
• Explore the interface between aging and senescence and tissue injury and fibrosis.
• Learn how single-cell genomics has informed: cellular heterogeneity; mechanisms driving tissue injury and fibrosis; and cells/pathways that can be reprogrammed to promote repair and regeneration.
• Review translational advances supporting the understanding of fibrotic disease and facilitating drug development: models of human disease; prognostic markers of disease susceptibility; biomarkers of disease activity; and non-invasive technologies to diagnose, prognosticate, and monitor therapeutic intervention.
• Highlight recent advances toward developing novel fibrosis therapies.
This renowned meeting will provide an interactive forum for early and established international investigators, highlight novel discoveries and facilitate fruitful collaboration. It will include mentoring and training during the workshops and poster sessions and in-depth discussions throughout the meeting. No other meeting delivers this scope of topics and opportunity for interaction and scientific collaboration.